Genomic Health Inc. (NASDAQ:GHDX) shares shot up 1.7% during mid-day trading on Thursday . The stock traded as high as $26.97 and last traded at $26.73, with a volume of 106,183 shares trading hands. The stock had previously closed at $26.29.

Several brokerages have recently issued reports on GHDX. Canaccord Genuity reaffirmed a “buy” rating on shares of Genomic Health in a research note on Thursday, May 5th. Zacks Investment Research lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Thursday, August 4th. Bank of America Corp. set a $28.00 target price on shares of Genomic Health and gave the company a “sell” rating in a research note on Wednesday, August 3rd. Leerink Swann reaffirmed a “buy” rating on shares of Genomic Health in a research note on Thursday, May 26th. Finally, Jefferies Group lifted their price objective on shares of Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, August 17th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $32.44.

The company’s market cap is $883.67 million. The company has a 50 day moving average of $28.01 and a 200 day moving average of $26.58.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.18) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.18). The firm had revenue of $81.97 million for the quarter, compared to analysts’ expectations of $81.27 million. The business’s quarterly revenue was up 16.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.29) earnings per share. Analysts anticipate that Genomic Health Inc. will post ($0.47) earnings per share for the current fiscal year.

In other news, Director Felix Baker acquired 100,000 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The shares were bought at an average cost of $27.02 per share, with a total value of $2,702,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction dated Thursday, June 9th. The shares were sold at an average price of $26.62, for a total value of $133,100.00. Following the transaction, the chief operating officer now directly owns 40,226 shares in the company, valued at $1,070,816.12. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Genomic Health stock. Schwab Charles Investment Management Inc. boosted its position in shares of Genomic Health Inc. (NASDAQ:GHDX) by 16.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 65,765 shares of the company’s stock after buying an additional 9,308 shares during the period. Schwab Charles Investment Management Inc. owned 0.20% of Genomic Health worth $2,315,000 at the end of the most recent quarter.

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.